A Phase 3 interventional study of migalastat hydrochloride and Placebo in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 28 sites in 13 countries. Open to participants aged 16 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-10-30.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 11 in phase 3, and was the 6th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 16 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2009.
This study's enrollment of 67 is above the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2009, is one of 8 in phase 3, and was the 6th registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to compare the effect of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).
This double-blind, randomized, placebo-controlled study was conducted in 67 participants at 46 sites worldwide. The study consisted of 2 stages and an optional open-label treatment extension phase:
Stage 1 included a screening period of up to 2 months followed by a 6-month treatment period which involved 4 visits to the clinic. Participants were randomized in equal proportions to receive either migalastat or placebo.
After completing the 6-month double-blind phase, all participants entered Stage 2 of the study and received migalastat in an open-label manner. Stage 2 treatment lasted for 6 months and involved up to 4 visits to the clinic.
Participants who completed both Stage 1 and Stage 2 of the study as scheduled were offered the opportunity to participate in an open-label treatment extension phase with migalastat. The open-label treatment extension phase lasted 12 months and involved 2 visits to the clinic. A follow-up visit was undertaken 1 month following completion or discontinuation from the open-label treatment extension. Participants completing the 12-month open-label treatment extension and providing consent to enter a separate long-term extension were not required to complete this follow-up visit.
Study assessments included clinical laboratory tests, 12-lead electrocardiogram, kidney biopsy, kidney function testing, echocardiography, and patient-reported outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
Drug: migalastat hydrochloride
Placebo capsule taken orally QOD for 6 months.
Drug: Placebo
Oral capsule QOD
Also known as: AT1001, Galafold, Migalastat
Oral capsule QOD
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions
Renal biopsies were taken at Baseline and Month 6 (Stage 1). The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images. A responder was defined as a participant with a ≥50% reduction from Baseline to Month 6 in the average number of kidney IC GL-3 inclusions.
Time frame: Baseline, Month 6
Percent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6
Renal biopsies were taken at Baseline and Month 6. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images.
Time frame: Baseline, Month 6
Change From Baseline Through Month 24 In Urine GL-3 Levels
The effect of migalastat versus placebo on urine GL-3 levels was measured by liquid chromatography-mass spectrometry/mass spectrometry. The 24-hour urine samples were collected at Baseline, Month 6 (Stage 1), Month 12 (Stage 2), and Month 24 (OLE). Results are presented as changes in nanograms (ng)/mg creatinine from Baseline to the end of the 3 stages.
Time frame: Baseline, Months 6, 12, and 24
Change From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions
Renal biopsies were taken at Month 6 and Month 12. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Month 6 and Month 12. Assessments were made using digital images.
Time frame: Month 6, Month 12
| Milestone | Migalastat (0-6 Months) | Placebo (0-6 Months) | Migalastat (>6-12 Months) | Migalastat (>12-24 Months) |
|---|---|---|---|---|
| Started | 34 | 33 | 0 | 0 |
| Received at least 1 dose of study drug | 34 | 33 | 0 | 0 |
| Intent-to-treat (itt) | 34 | 33 | 0 | 0 |
| Modified intent-to-treat (mitt) | 30 | 30 | 0 | 0 |
| Completed | 34 | 30 | 0 | 0 |
| Not completed | 0 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Milestone | Migalastat (0-6 Months) | Placebo (0-6 Months) | Migalastat (>6-12 Months) | Migalastat (>12-24 Months) |
|---|---|---|---|---|
| Started | 0 | 0 | 63 | 0 |
| Itt-amenable | 0 | 0 | 47 | 0 |
| Completed | 0 | 0 | 60 | 0 |
| Not completed | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Milestone | Migalastat (0-6 Months) | Placebo (0-6 Months) | Migalastat (>6-12 Months) | Migalastat (>12-24 Months) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 57 |
| Itt-amenable | 0 | 0 | 0 | 42 |
| Completed | 0 | 0 | 0 | 54 |
| Not completed | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
Renal biopsies were taken at Baseline and Month 6 (Stage 1). The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images. A responder was defined as a participant with a ≥50% reduction from Baseline to Month 6 in the average number of kidney IC GL-3 inclusions.
| Participants | Migalastat | Placebo |
|---|---|---|
| Responder | 13 | 9 |
| Non-Responder | 19 | 23 |
Renal biopsies were taken at Baseline and Month 6. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images.
| percent change | Migalastat | Placebo |
|---|---|---|
| Percent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6 | -7.948 ± 105.2736 | 12.985 ± 90.5131 |
The effect of migalastat versus placebo on urine GL-3 levels was measured by liquid chromatography-mass spectrometry/mass spectrometry. The 24-hour urine samples were collected at Baseline, Month 6 (Stage 1), Month 12 (Stage 2), and Month 24 (OLE). Results are presented as changes in nanograms (ng)/mg creatinine from Baseline to the end of the 3 stages.
| ng/mg creatinine | Migalastat-Migalastat | Placebo-Migalastat |
|---|---|---|
| Stage 1 | -234.80 ± 853.451 | -186.24 ± 957.119 |
| Stage 2 | -179.63 ± 699.157 | -537.95 ± 1169.883 |
| OLE | -62.37 ± 615.944 | -177.42 ± 288.224 |
Renal biopsies were taken at Month 6 and Month 12. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Month 6 and Month 12. Assessments were made using digital images.
| kidney IC GL-3 inclusions | Placebo-Migalastat |
|---|---|
| Change From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions | -0.320 (-0.5719 to -0.0677) |
Renal biopsies were taken at Baseline and Month 6. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images. Treatment effect was estimated using the LS mean difference between treatments within the context of the ANCOVA model.
| kidney IC GL-3 inclusions | Migalastat |
|---|---|
| Change From Baseline To Month 6 In Average Number Of Kidney IC GL-3 Inclusions | -0.250 ± 0.5126 |
Collected over Adverse events (AEs) were monitored up to 25 months (±7 days) after the first dose of study drug. AEs were reported from the first dose of study medication at Baseline (Visit 1) in Stage 1 to 1 month (±7 days) after the date of the last study visit, whether during Stage 1, Stage 2, or the optional OLE, or after premature discontinuation from the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Migalastat (0-6 Months) | — | 2/34 (5.9%) | 31/34 (91.2%) |
| Placebo (0-6 Months) | — | 4/33 (12.1%) | 30/33 (90.9%) |
| All Migalastat (>6-12 Months) | — | 5/63 (7.9%) | 50/63 (79.4%) |
| All Migalastat (>12-24 Months) | — | 11/57 (19.3%) | 46/57 (80.7%) |
| Event | Migalastat (0-6 Months) | Placebo (0-6 Months) | All Migalastat (>6-12 Months) | All Migalastat (>12-24 Months) |
|---|---|---|---|---|
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/34 | 0/33 | 2/63 | 0/57 |
| Post Procedural HaemorrhageInjury, poisoning and procedural complications | 0/34 | 1/33 | 0/63 | 0/57 |
| Anaplastic Large Cell Lymphoma T - and Null - Cell TypesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 1/33 | 0/63 | 0/57 |
| Bacterial InfectionInfections and infestations | 0/34 | 1/33 | 0/63 | 0/57 |
| Meningitis ViralInfections and infestations | 0/34 | 1/33 | 0/63 | 0/57 |
| Post Procedural HaematomaInjury, poisoning and procedural complications | 1/34 | 0/33 | 0/63 | 0/57 |
| HydronephrosisRenal and urinary disorders | 1/34 | 0/33 | 0/63 | 0/57 |
| Multiple FracturesInjury, poisoning and procedural complications | 0/34 | 0/33 | 0/63 | 1/57 |
| PalpitationsCardiac disorders | 0/34 | 0/33 | 0/63 | 1/57 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/34 | 0/33 | 0/63 | 1/57 |
| Event | Migalastat (0-6 Months) | Placebo (0-6 Months) | All Migalastat (>6-12 Months) | All Migalastat (>12-24 Months) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 12/34 | 7/33 | 9/63 | 6/57 |
| NasopharyngitisInfections and infestations | 6/34 | 2/33 | 5/63 | 3/57 |
| ProteinuriaRenal and urinary disorders | 0/34 | 0/33 | 1/63 | 9/57 |
| FatigueGeneral disorders | 4/34 | 4/33 | 2/63 | 3/57 |
| ParaesthesiaNervous system disorders | 4/34 | 4/33 | 4/63 | 2/57 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 0/34 | 4/33 | 2/63 | 2/57 |
| PyrexiaGeneral disorders | 4/34 | 1/33 | 1/63 | 0/57 |
| NauseaGastrointestinal disorders | 4/34 | 2/33 | 2/63 | 3/57 |
| Procedural PainInjury, poisoning and procedural complications | 2/34 | 1/33 | 7/63 | 0/57 |
| BronchitisInfections and infestations | 1/34 | 0/33 | 1/63 | 6/57 |
Safety Population: All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Migalastat-Migalastat | Placebo-Migalastat | Total |
|---|---|---|---|
| Mean | 40.0 ± 13.29 | 44.5 ± 10.18 | 42.2 ± 11.99 |
| Sex: Female, Male(Participants) | Migalastat-Migalastat | Placebo-Migalastat | Total |
|---|---|---|---|
| Female | 22 | 21 | 43 |
| Male | 12 | 12 | 24 |
Ran from Oct 2009 to primary completion in Jun 2012, 31 months.
Results were first posted in Oct 2018, 6 years 4 months after primary completion. A results delay was requested in Sep 2013.
Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat